

Malaria

Malaria – Diagnosis and Management



Malaria is a medical emergency
Do not delay treatment
Do NOT delay therapy if pregnant as benefit outweighs risk



Malaria should be suspected in all patients with pyrexia and recent travel to/from a malarial area (within the previous 6 months)

- Request urgent Malaria Screen – malaria antigen and thick and thin blood film
- For recent outbreak information and guidelines available see “Additional Information” section below

Admission and ID consult advised

Blood cultures & tests (FBC, U&E, blood glucose, ABG & CXR where applicable)

Routine and directed diagnostic work-up recommended to exclude other travel related infections

Complete HIV testing

ASSESSMENT of patient with possible malaria

- Symptoms may be non-specific: fevers/chills/sweats, malaise, myalgia, headache, diarrhoea and/or cough
- Consider which malaria prophylaxis was taken (drug, dose, adherence). Note full adherence does not exclude malaria
- Assess for features of complicated malaria:
 - ❖ Impaired consciousness
 - ❖ Renal impairment
 - ❖ Acidosis (base deficit of >8mmol/L or bicarbonate of <15mmol/L or venous lactate ≥5 mmol/L)
 - ❖ Hypoglycaemia
 - ❖ Pulmonary oedema
 - ❖ Anaemia
 - ❖ Prostration
 - ❖ Jaundice
 - ❖ Spontaneous bleeding/Disseminated Intravascular Coagulation (DIC)
 - ❖ Shock
- Note three negative diagnostic samples over 24-48 hours are necessary to exclude malaria

MANAGEMENT

- Consider broad spectrum antibiotics if evidence of shock or secondary bacterial infection
- Consider ICU review and monitored bed
- IV fluid resuscitation with strict observation and management of fluid status
- Close monitoring of blood glucose (hypoglycaemia), renal function, Hb, clotting and electrolytes recommended
- Consider cerebral malaria – impaired consciousness or seizures

CLASSIFICATION

Severe/Complicated

- Parasitaemia >2%
- Parasitaemia <2% with features of complicated malaria/unable to tolerate oral medications/other comorbidities

Non Severe/Uncomplicated

- Parasitaemia <2% and able to tolerate PO and no comorbidities/complications

Malaria - Treatment

Factors to consider when deciding treatment

1. Severity Of Illness

Severe/Complicated

Parasitaemia >2%

Parasitaemia <2% with one or more of the following:
1. Features of complicated malaria
2. Unable to tolerate oral medications
3. Other comorbidities

Non-Severe/Uncomplicated

Parasitaemia <2%

AND able to tolerate oral
AND no comorbidities/complications

2. Organism Involved

P. falciparum

P. knowlesi

P. ovale

P. vivax

P. malariae

Not identified

OUT OF HOURS MEDICATION SUPPLY

Please refer to local hospital policy for out of hours medication supply

MEDICATION CONSIDERATION

- **Artesunate**: Monitor for haemolysis and renal function 4 weeks after administration
- **Primaquine**: Check G6PD deficiency before using. Contraindicated in pregnancy
- **Quinine**: Continuous cardiac monitoring & glucose monitoring required for IV therapy
- **Riamet**® (Artemether/Lumefantrine): Limited safety data and not recommended in 1st trimester of pregnancy without specialist advice.
- Artesunate and Quinine can be given IM as a last resort. IV route preferred
- Artesunate, Primaquine, Quinine and Riamet are unlicensed medications, thus the prescribing doctor must take full responsibility

P. falciparum/*P. knowlesi*/*P. malariae*/unidentified

Severe/Complicated

1st Line: Artesunate® IV: 2.4mg/kg, repeat after 12 and 24 hours, then once daily to a total dose of 12mg/kg (5 doses over the 3 days). Followed by completion of oral therapy: Artemether/Lumefantrine (Riamet®) (Body weight ≥35kg) 80mg/480mg at 0,8,24,36,48 & 60 hours.

2nd Line: Quinine Dihydrochloride IV: loading dose 20mg/kg (max dose=1.4g) infused over 4 hours, then 8 hours after the start of the loading dose infusion, give 10mg/kg (max dose=700mg) every 8 hours. Switch to PO quinine sulphate 600mg TDS and PO doxycycline 200mg OD once PO tolerated/parasite count decreased. Complete full course of 7 days of PO therapy.

Non-Severe/Uncomplicated

Treat with Artemether/Lumefantrine (Riamet®) as above.

P. ovale/*P. vivax*

As per *P. falciparum*

Subsequent use of Primaquine 0.5mg/kg OD PO(max dose of 30mg) for 14 days (for hepatic hypnozoite eradication)
For Hepatic hypnozoite eradication in pregnancy discuss with ID.

References:

1. WHO Guidelines for Malaria 4th edition (2022). <https://www.who.int/publications/i/item/guidelines-for-malaria>
2. BIA UK Treatment of Malaria guideline 2016 j infect (2016) 72. 635-649
3. RCOG Malaria in Pregnancy diagnosis and treatment (2010)

Adapted from UHW Malaria Guideline
Ver 2.1 Aug 2023

PREGNANCY

Severe/Complicated

1st Line: As for *P. falciparum*. IV Artesunate for all trimesters. Please discuss with specialist on oral therapy following IV Artesunate.

2nd Line: Quinine IV: As for *P. falciparum* AND PO clindamycin 450mg TDS. Switch to PO quinine 600mg TDS AND PO clindamycin 450mg TDS once PO tolerated/parasite count decreased. Complete full course of 7 days of PO therapy.

Non-Severe/Uncomplicated

1st trimester

PO quinine 600mg TDS AND PO clindamycin 450mg TDS for 7 days

2nd /3rd trimester

Treat with artemether/lumefantrine (Riamet®) as above

OR

PO quinine 600mg TDS AND PO clindamycin 450mg TDS for 7 days
For hepatic hypnozoite eradication in pregnancy discuss with ID

Additional Information

- For recent outbreak information see www.cdc.gov/travel
- Guidelines available at www.who.int/publications/i/item/guidelines-for-malaria